BR112014014323A2 - uso de excipientes poliméricos para liofilização ou congelamento de partículas - Google Patents
uso de excipientes poliméricos para liofilização ou congelamento de partículasInfo
- Publication number
- BR112014014323A2 BR112014014323A2 BR112014014323A BR112014014323A BR112014014323A2 BR 112014014323 A2 BR112014014323 A2 BR 112014014323A2 BR 112014014323 A BR112014014323 A BR 112014014323A BR 112014014323 A BR112014014323 A BR 112014014323A BR 112014014323 A2 BR112014014323 A2 BR 112014014323A2
- Authority
- BR
- Brazil
- Prior art keywords
- polymeric excipients
- freeze drying
- particle freezing
- freezing
- particle
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 4
- 238000004108 freeze drying Methods 0.000 title abstract 2
- 238000007710 freezing Methods 0.000 title abstract 2
- 230000008014 freezing Effects 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570735P | 2011-12-14 | 2011-12-14 | |
| PCT/US2012/069585 WO2013090634A1 (en) | 2011-12-14 | 2012-12-13 | Use of polymeric excipients for lyophilization or freezing of particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014014323A2 true BR112014014323A2 (pt) | 2017-06-13 |
Family
ID=48613191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014323A BR112014014323A2 (pt) | 2011-12-14 | 2012-12-13 | uso de excipientes poliméricos para liofilização ou congelamento de partículas |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9585960B2 (enExample) |
| EP (2) | EP3560486A1 (enExample) |
| JP (2) | JP6216721B2 (enExample) |
| KR (2) | KR102203555B1 (enExample) |
| CN (2) | CN104114159B (enExample) |
| AU (2) | AU2012352167B2 (enExample) |
| BR (1) | BR112014014323A2 (enExample) |
| CA (1) | CA2858593C (enExample) |
| CY (1) | CY1122105T1 (enExample) |
| DK (1) | DK2790675T3 (enExample) |
| ES (1) | ES2746057T3 (enExample) |
| HR (1) | HRP20191567T1 (enExample) |
| HU (1) | HUE045661T2 (enExample) |
| IL (1) | IL233000B (enExample) |
| LT (1) | LT2790675T (enExample) |
| ME (1) | ME03532B (enExample) |
| MX (2) | MX374915B (enExample) |
| PL (1) | PL2790675T3 (enExample) |
| PT (1) | PT2790675T (enExample) |
| RS (1) | RS59322B1 (enExample) |
| RU (2) | RU2705998C2 (enExample) |
| SI (1) | SI2790675T1 (enExample) |
| SM (1) | SMT201900502T1 (enExample) |
| WO (1) | WO2013090634A1 (enExample) |
| ZA (1) | ZA201404262B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| KR102780168B1 (ko) * | 2018-05-21 | 2025-03-11 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
| RU2681933C1 (ru) * | 2018-11-28 | 2019-03-14 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Способ получения полимерных противоопухолевых частиц в проточном микрореакторе и лиофилизата на их основе |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| BR112023002642A2 (pt) | 2020-08-14 | 2023-04-04 | Arcturus Therapeutics Inc | Método para liofilizar nanopartículas lipídicas |
| WO2024046448A1 (en) * | 2022-09-02 | 2024-03-07 | Suzhou Abogen Biosciences Co., Ltd. | Lyophilized formulations and liquid formulations of lipid nanoparticles |
| WO2024077054A1 (en) * | 2022-10-05 | 2024-04-11 | Purdue Research Foundation | Excipient-free lyophilization of polymer lung surfactants |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2018734A1 (de) | 1970-04-18 | 1971-10-28 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches Verfahren |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| PT693924E (pt) | 1993-02-22 | 2004-09-30 | American Biosciences | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| DE59409568D1 (de) * | 1993-09-09 | 2000-11-30 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US6537539B2 (en) | 1996-01-11 | 2003-03-25 | Human Genome Sciences, Inc. | Immune cell cytokine |
| US7368129B1 (en) * | 1996-08-14 | 2008-05-06 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| AU1093900A (en) * | 1998-09-21 | 2000-04-10 | 21St Century Medicine, Inc. | Improved cryoprotectant solutions |
| KR100321854B1 (ko) * | 1998-12-30 | 2002-08-28 | 동국제약 주식회사 | 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법 |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| EP1178786A4 (en) | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
| AR023940A1 (es) | 2000-05-03 | 2002-09-04 | Eriochem Sa | Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| AU2002233239B2 (en) | 2000-12-13 | 2006-05-11 | Merckle Gmbh | Microparticles with an improved release profile and method for the production thereof |
| US8137699B2 (en) | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
| JP2003012505A (ja) * | 2001-07-06 | 2003-01-15 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥 |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| CN1398585A (zh) * | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLA－PEG缓释微球及其制备方法和用途 |
| NZ541142A (en) | 2002-12-09 | 2008-07-31 | Abraxis Bioscience Inc | Compositions and methods of delivery of pharmacological agents |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| JP4851067B2 (ja) * | 2004-01-28 | 2012-01-11 | ホソカワミクロン株式会社 | ナノ粒子含有組成物およびその製造方法 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP2006321763A (ja) * | 2005-05-20 | 2006-11-30 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 生体適合性ナノ粒子及びその製造方法 |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20100034892A1 (en) * | 2006-08-30 | 2010-02-11 | The Trustees Of Columbia University In The City Of New York | Treatment for bone formation disorders by growth factor delivery |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| MX2009002054A (es) | 2006-08-31 | 2009-05-01 | Abraxis Bioscience Llc | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| WO2009126175A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| AU2009234127B2 (en) | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2367425B1 (en) | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| US8846096B2 (en) | 2008-12-12 | 2014-09-30 | Creighton University | Nanoparticles and methods of use |
| EP2201935B1 (en) * | 2008-12-26 | 2020-07-08 | Samyang Biopharmaceuticals Corporation | Polymeric micelle composition containing a poorly soluble drug and preparation method of the same |
| WO2010105172A1 (en) | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| EP2413901A4 (en) * | 2009-03-30 | 2015-05-06 | Cerulean Pharma Inc | POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES |
| BRPI1014160A2 (pt) | 2009-04-10 | 2015-08-25 | Abraxis Bioscience Llc | Formulações de nanopartículas e aplicações das mesmas |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| SG178873A1 (en) | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| WO2011072218A2 (en) | 2009-12-11 | 2011-06-16 | Bind Biosciences | Stable formulations for lyophilizing therapeutic particles |
| WO2011119995A2 (en) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| NZ707377A (en) | 2010-06-07 | 2015-09-25 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| EA201390145A1 (ru) * | 2010-08-20 | 2013-11-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции и связанные с ними способы |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| EP2953622B1 (en) | 2013-02-11 | 2021-03-24 | Abraxis BioScience, LLC | Methods of treating melanoma |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| KR20150126671A (ko) | 2013-03-13 | 2015-11-12 | 아브락시스 바이오사이언스, 엘엘씨 | 소아 고형 종양의 치료 방법 |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| MX2017016491A (es) | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). |
| HK1254398A1 (zh) | 2015-06-29 | 2019-07-19 | Abraxis Bioscience, Llc | 納米粒子組合物的生物標誌物 |
| US20180153863A1 (en) | 2015-06-29 | 2018-06-07 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
| US20190147986A1 (en) | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| AU2017343553A1 (en) | 2016-10-10 | 2019-05-02 | Abraxis Bioscience, Llc | Nanoparticle formulations and methods of making and using thereof |
| US20180374583A1 (en) | 2017-05-16 | 2018-12-27 | Abraxis Bioscience, Llc | Nomogram and survival predictions for pancreatic cancer |
| US20190184031A1 (en) | 2017-12-19 | 2019-06-20 | Abraxis Bioscience, Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
-
2012
- 2012-12-13 EP EP19175097.5A patent/EP3560486A1/en not_active Withdrawn
- 2012-12-13 ME MEP-2019-243A patent/ME03532B/me unknown
- 2012-12-13 HR HRP20191567 patent/HRP20191567T1/hr unknown
- 2012-12-13 EP EP12858155.0A patent/EP2790675B1/en active Active
- 2012-12-13 RU RU2014128590A patent/RU2705998C2/ru active
- 2012-12-13 WO PCT/US2012/069585 patent/WO2013090634A1/en not_active Ceased
- 2012-12-13 RU RU2019134053A patent/RU2019134053A/ru not_active Application Discontinuation
- 2012-12-13 MX MX2017013375A patent/MX374915B/es unknown
- 2012-12-13 US US14/362,382 patent/US9585960B2/en active Active
- 2012-12-13 HU HUE12858155A patent/HUE045661T2/hu unknown
- 2012-12-13 BR BR112014014323A patent/BR112014014323A2/pt not_active Application Discontinuation
- 2012-12-13 JP JP2014547445A patent/JP6216721B2/ja active Active
- 2012-12-13 AU AU2012352167A patent/AU2012352167B2/en active Active
- 2012-12-13 KR KR1020207007231A patent/KR102203555B1/ko active Active
- 2012-12-13 SI SI201231666T patent/SI2790675T1/sl unknown
- 2012-12-13 PT PT12858155T patent/PT2790675T/pt unknown
- 2012-12-13 DK DK12858155.0T patent/DK2790675T3/da active
- 2012-12-13 RS RSP20191151 patent/RS59322B1/sr unknown
- 2012-12-13 LT LT12858155T patent/LT2790675T/lt unknown
- 2012-12-13 CN CN201280069714.7A patent/CN104114159B/zh active Active
- 2012-12-13 PL PL12858155T patent/PL2790675T3/pl unknown
- 2012-12-13 ES ES12858155T patent/ES2746057T3/es active Active
- 2012-12-13 CN CN201811311225.3A patent/CN109771377A/zh active Pending
- 2012-12-13 KR KR1020147019063A patent/KR20140107417A/ko not_active Ceased
- 2012-12-13 CA CA2858593A patent/CA2858593C/en active Active
- 2012-12-13 SM SM20190502T patent/SMT201900502T1/it unknown
- 2012-12-13 MX MX2014007096A patent/MX354859B/es active IP Right Grant
-
2014
- 2014-06-08 IL IL233000A patent/IL233000B/en active IP Right Grant
- 2014-06-10 ZA ZA2014/04262A patent/ZA201404262B/en unknown
-
2017
- 2017-01-23 US US15/412,897 patent/US10076501B2/en active Active
- 2017-09-25 JP JP2017183764A patent/JP2017218462A/ja active Pending
- 2017-10-05 AU AU2017239541A patent/AU2017239541B2/en active Active
-
2018
- 2018-08-21 US US16/107,419 patent/US10555912B2/en active Active
-
2019
- 2019-09-04 CY CY20191100927T patent/CY1122105T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014323A2 (pt) | uso de excipientes poliméricos para liofilização ou congelamento de partículas | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| BR112014004460A2 (pt) | material polimérico para um recipiente isolado | |
| WO2015048498A3 (en) | Carrier-free biologically-active protein nanostructures | |
| BR112015011235A2 (pt) | sistema de travamento mecânico para painéis de piso | |
| CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| BR112013033319A2 (pt) | composição compreendendo quitosana, glucosamina e aminoácidos para uso agrícola | |
| BR112014016889A2 (pt) | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 | |
| MX373916B (es) | Composicion topica de ketoprofeno. | |
| AR086682A1 (es) | Formulacion de aripiprazol liofilizado | |
| EP4509163A3 (en) | Graft anchor devices, systems, and methods | |
| WO2012106281A3 (en) | Multimodal trail molecules and uses in cellular therapies | |
| PL2612551T3 (pl) | Kompozycja roztoczy zawierająca roztocza drapieżnego i unieruchomiony żer w kontakcie ze środkiem ograniczającym grzyby oraz sposoby i zastosowania dotyczące stosowania wspomnianej kompozycji | |
| WO2012116073A3 (en) | Amphiphilic dendron-coils, micelles thereof and uses | |
| BR112014025041B8 (pt) | Composição farmacêutica | |
| CL2014001115A1 (es) | Formulación para la preservación de la madera comprendiendo un agente biocida el cual es un ion de cobre o un zinc complejado con un compuesto amino y un polímero cationico; producto combinado; solución y sistema de tratamiento; método para la preservacion; sustrato; metodo para hacer la formulacion; y uso del polimero cationico. | |
| IT1401531B1 (it) | Sistema utilizzabile in due modalita' | |
| BR112015013071A2 (pt) | solução de trombina e seus métodos de uso | |
| WO2012125552A3 (en) | Methods of electric field induced delivery of compounds, compositions used in delivery, and system of delivery | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| WO2015018567A3 (de) | Formulierung enthaltend caprylsäureethanolamid und/oder caprinsäureethanolamid in kombination mit einem tensid | |
| WO2014031982A3 (en) | Methods and compositions for treating pain | |
| BR112015004115A2 (pt) | composições farmacêuticas compreendendo flurbiprofeno | |
| WO2015001524A3 (en) | Stabilization of rose dedifferentiated cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |